Diabetic nephropathy (DN) is a major complication of diabetes mellitus that causes progressive renal dysfunction. Early diagnosis and monitoring are limited by a shortage of robust molecular biomarkers. Mounting evidence implicates oxidative stress—including elevated levels of reactive oxygen species such as the superoxide anion (O2·-)—in the pathogenesis and progression of DN. The study summarized here aimed to address the need for tools that can directly visualize and monitor oxidative activity associated with DN.
The authors report development of an activatable fluorescent probe named CZY that localizes to mitochondria and is activated selectively by superoxide anion. According to the abstract, CZY shows high selectivity toward O2·-, chemical stability under the conditions studied, and favorable biocompatibility. These attributes position CZY as a candidate molecular imaging reagent for detecting mitochondrial oxidative events in renal cells and tissues. The abstract does not provide the full chemical structure, synthetic route, or quantitative analytical performance metrics (for example, limit of detection, reaction kinetics, or cross-reactivity data); those details are available only in the full article.
In cultured renal collecting-duct cells (mIMCD-3), the probe CZY enabled visualization of oxidative activity that was associated with superoxide. Imaging with CZY revealed time-dependent changes in O2·--related signals within these cells, demonstrating the probe's ability to monitor dynamic alterations in intracellular oxidative state. The abstract indicates successful use in a cellular context, and reports favorable biocompatibility, implying that CZY did not produce overt cytotoxicity under the tested conditions. The specific experimental parameters used for cellular imaging—such as probe concentration, incubation times, excitation/emission wavelengths, microscope modality, and quantitative readouts—are not included in the abstract and should be consulted in the full text for implementation.
Beyond cell culture, CZY was applied in a diabetic nephropathy model to visualize variations in superoxide levels. The authors describe the probe as enabling spatiotemporal visualization of O2·- in the DN model, supporting its use as an effective molecular imaging platform for monitoring changes in superoxide associated with DN pathology. The abstract does not specify whether the DN model was in vitro, ex vivo, or in vivo, nor does it report quantitative outcome measures, model species or induction method, imaging timepoints, or how imaging correlated with histopathology or functional renal endpoints. Those experimental specifics will be found in the full article.
The study concludes that imaging mitochondrial superoxide with a selective activatable probe clarifies the oxidative stress level in diabetic nephropathy. By enabling spatiotemporal monitoring of O2·-, CZY may provide a useful basis for subsequent diagnostic and therapeutic exploration. Potential applications suggested by the abstract include using CZY as a research tool to track oxidative dynamics during DN progression, to evaluate the effects of antioxidant or other therapeutic interventions on mitochondrial ROS, and to help identify oxidative biomarkers relevant to early diagnosis. Concrete clinical translation pathways, regulatory considerations, or prospective diagnostic performance were not addressed in the abstract.
This work is reported in Mikrochimica Acta (2026); the PubMed identifier is PMID 42700281 and the DOI is 10.1007/s00604-026-08379-8. Multiple authors affiliated with research and clinical institutions in China contributed to the study. The abstract lists keywords including Diabetic nephropathy, Fluorescent probe, Oxidative stress, and Superoxide anion. The authors declare no competing interests.
Note on available information
The abstract provides a concise summary of probe development, in vitro cellular imaging results, and application in a DN model. However, many implementation and performance details—such as chemical structure and synthesis of CZY, quantitative selectivity and sensitivity data, complete imaging protocols, model specifics, and statistical outcomes—are not reported in the abstract and require access to the full manuscript for comprehensive evaluation.